FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3119003066> ?p ?o ?g. }

• W3119003066 endingPage "145" @default.
• W3119003066 startingPage "133" @default.
• W3119003066 abstract "Rheumatoid arthritis (RA) is an autoimmune disease that underlies chronic inflammation of the synovial membrane. Non-steroidal anti-inflammatory drugs (NSAIDs) are commonly used to treat RA. However, a long list of adverse events associated with long-term treatment regimens with NSAIDs negatively influences patient compliance and therapeutic outcomes.The aim of this work was to achieve site-specific delivery of celecoxib-loaded spanlastic nano-vesicle-based delivery system to the inflamed joints, avoiding systemic administration of large doses.To develop spanlastic nanovesicles for transdermal delivery of celecoxib, modified injection method was adopted using Tween 80 or Brij as edge activators. Entrapment efficiency, vesicle size, ex vivo permeation, and morphology of the prepared nano-vesicles were characterized. Carbopol-based gels containing the selected formulations were prepared, and their clarity, pH, rheological performance, and ex vivo permeation were characterized. Celecoxib-loaded niosomes and noisome-containing gels were developed for comparison. The in vivo efficacy of the selected formulations was evaluated in a rat model of Freund's complete adjuvant-induced arthritis. Different inflammatory markers including TNF-α, NF-кB and COX-2 were assessed in paw tissue before and after treatment.The size and entrapment efficiency of the selected spanlastic nano-vesicle formulation were 112.5 ± 3.6 nm, and 83.6 ± 2.3%, respectively. This formulation has shown the highest transdermal flux and permeability coefficient compared to the other investigated formulations. The spanlastics-containing gel of celecoxib has shown transdermal flux of 6.9 ± 0.25 µg/cm2/hr while the celecoxib niosomes-containing gel and unprocessed celecoxib-loaded gel have shown 5.2 ± 0.12 µg/cm2/hr and 0.64 ± 0.09 µg/cm2/hr, respectively. In the animal model of RA, the celecoxib-loaded spanlastics-containing gel significantly reduced edema circumference and significantly suppressed TNF-α, NF-кB and COX-2 levels compared to the niosomes-containing gel, the marketed diclofenac sodium gel, and unprocessed celecoxib-loaded gel.The spanlastic nano-vesicle-containing gel represents a more efficient site-specific treatment for topical treatment of chronic inflammation like RA, compared to commercial and other conventional alternatives." @default.
• W3119003066 created "2021-01-18" @default.
• W3119003066 creator A5001091510 @default.
• W3119003066 creator A5023024053 @default.
• W3119003066 creator A5023994657 @default.
• W3119003066 creator A5030946673 @default.
• W3119003066 creator A5051312605 @default.
• W3119003066 creator A5087947799 @default.
• W3119003066 date "2021-01-01" @default.
• W3119003066 modified "2023-10-17" @default.
• W3119003066 title "Topical Nano-Vesicular Spanlastics of Celecoxib: Enhanced Anti-Inflammatory Effect and Down-Regulation of TNF-α, NF-кB and COX-2 in Complete Freund’s Adjuvant-Induced Arthritis Model in Rats" @default.
• W3119003066 cites W1512721670 @default.
• W3119003066 cites W1521338784 @default.
• W3119003066 cites W1972451253 @default.
• W3119003066 cites W1973231585 @default.
• W3119003066 cites W1995243183 @default.
• W3119003066 cites W2001118253 @default.
• W3119003066 cites W2008243145 @default.
• W3119003066 cites W2012528729 @default.
• W3119003066 cites W2027313185 @default.
• W3119003066 cites W2028080874 @default.
• W3119003066 cites W2031102369 @default.
• W3119003066 cites W2033362260 @default.
• W3119003066 cites W2044453617 @default.
• W3119003066 cites W2044600270 @default.
• W3119003066 cites W2044923647 @default.
• W3119003066 cites W2053721340 @default.
• W3119003066 cites W2055671404 @default.
• W3119003066 cites W2057789991 @default.
• W3119003066 cites W2058009653 @default.
• W3119003066 cites W2060139782 @default.
• W3119003066 cites W2062436855 @default.
• W3119003066 cites W2076687382 @default.
• W3119003066 cites W2080839858 @default.
• W3119003066 cites W2084774646 @default.
• W3119003066 cites W2086889742 @default.
• W3119003066 cites W2087971910 @default.
• W3119003066 cites W2095421778 @default.
• W3119003066 cites W2103537781 @default.
• W3119003066 cites W2105461697 @default.
• W3119003066 cites W2118447282 @default.
• W3119003066 cites W2121932492 @default.
• W3119003066 cites W2128891694 @default.
• W3119003066 cites W2130435291 @default.
• W3119003066 cites W2135276021 @default.
• W3119003066 cites W2139258120 @default.
• W3119003066 cites W2143045184 @default.
• W3119003066 cites W2160063920 @default.
• W3119003066 cites W2173493992 @default.
• W3119003066 cites W2174548899 @default.
• W3119003066 cites W2231669397 @default.
• W3119003066 cites W2558749095 @default.
• W3119003066 cites W2571192017 @default.
• W3119003066 cites W2593626546 @default.
• W3119003066 cites W2594374499 @default.
• W3119003066 cites W2603978658 @default.
• W3119003066 cites W2626693444 @default.
• W3119003066 cites W2734929607 @default.
• W3119003066 cites W2739185300 @default.
• W3119003066 cites W2890151713 @default.
• W3119003066 cites W2913826149 @default.
• W3119003066 cites W2964574431 @default.
• W3119003066 cites W2967691925 @default.
• W3119003066 cites W2981579389 @default.
• W3119003066 cites W2982159405 @default.
• W3119003066 cites W2986104088 @default.
• W3119003066 cites W3014776212 @default.
• W3119003066 cites W3034126398 @default.
• W3119003066 cites W343173162 @default.
• W3119003066 cites W89717846 @default.
• W3119003066 doi "https://doi.org/10.2147/ijn.s289828" @default.
• W3119003066 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7802787" @default.
• W3119003066 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33447032" @default.
• W3119003066 hasPublicationYear "2021" @default.
• W3119003066 type Work @default.
• W3119003066 sameAs 3119003066 @default.
• W3119003066 citedByCount "36" @default.
• W3119003066 countsByYear W31190030662021 @default.
• W3119003066 countsByYear W31190030662022 @default.
• W3119003066 countsByYear W31190030662023 @default.
• W3119003066 crossrefType "journal-article" @default.
• W3119003066 hasAuthorship W3119003066A5001091510 @default.
• W3119003066 hasAuthorship W3119003066A5023024053 @default.
• W3119003066 hasAuthorship W3119003066A5023994657 @default.
• W3119003066 hasAuthorship W3119003066A5030946673 @default.
• W3119003066 hasAuthorship W3119003066A5051312605 @default.
• W3119003066 hasAuthorship W3119003066A5087947799 @default.
• W3119003066 hasBestOaLocation W31190030661 @default.
• W3119003066 hasConcept C130316041 @default.
• W3119003066 hasConcept C150903083 @default.
• W3119003066 hasConcept C185592680 @default.
• W3119003066 hasConcept C203014093 @default.
• W3119003066 hasConcept C205679159 @default.
• W3119003066 hasConcept C207001950 @default.
• W3119003066 hasConcept C26291073 @default.
• W3119003066 hasConcept C2776467144 @default.
• W3119003066 hasConcept C2777077863 @default.
• W3119003066 hasConcept C2777575956 @default.

• next